The leveraging of CRISPR-Cas9 technology to perform functional genomic screens has provided a powerful boost to elucidate gene functionality in the context of disease and drug discovery.
CRISPR-Cas9 screens, by allowing efficient homozygous gene knockout, have improved reproducibility relative to RNAi screens and have become the gold standard in functional genomics.
The adaptation of the system, by the use of a nuclease inactive form of Cas9, dCas9, has broadened its application by allowing genetic modulation of endogenous gene expression.
In this webinar we discuss:
- Considerations around the use of different CRISPR-Cas9 modalities
- Comparison of pooled vs arrayed CRISPR-Cas9 Screening
- Different formats of CRISPR-Cas9 screening approaches to answer a variety of research questions
The drug discovery pipeline has much to gain from utilising CRISPR-Cas9 screening - from mechanism of action studies to patient stratification. The choice of screen; pooled or arrayed, and the choice of CRISPR-Cas9 technology, depends on the question being asked, the material to be tested (from cell lines to organoids) and the functional read-out required.
